A new HPV vaccine induced regression of precancerous cervical lesions in 50% of patients and led to viral clearance in some ...

A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.

HPV vaccines aim to prevent the development of HPV-related cancers by stopping the viral infection from taking hold in the ...

A therapeutic vaccine targeting human papillomavirus type ... "Nearly all premalignant cervical lesions and cervical cancers are caused by HPV infection, with HPV16 implicated in the majority ...

An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive cervical intraepithelial neoplasia grade 3 (CIN3), according to results from ...

“Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16-associated CIN3 lesions and clearing the underlying persistent HPV16 ...

PHILADELPHIA – A therapeutic vaccine targeting human papillomavirus ... cervical lesions and cervical cancers are caused by HPV infection, with HPV16 implicated in the majority of cases ...

There was no clearance of other HPV types induced by Vvax001 ... “Our findings demonstrate that the therapeutic vaccine Vvax001 is safe, well-tolerated, and effective in eradicating HPV16 ...